(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(-1.22%) $77.99
(5.65%) $2.15
(0.02%) $2 310.10
(-0.16%) $26.79
(0.37%) $966.20
(-0.35%) $0.929
(-1.07%) $10.87
(-0.11%) $0.797
(0.35%) $91.45
5 days till quarter result
(tns 2024-05-10)
Expected move: +/- 11.24%
Live Chart Being Loaded With Signals
Frequency Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics to activate a person's innate regenerative potential to restore function...
Stats | |
---|---|
今日成交量 | 309 164 |
平均成交量 | 135 075 |
市值 | 10.94M |
EPS | $0 ( 2024-03-08 ) |
下一个收益日期 | ( $0 ) 2024-05-10 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.158 |
ATR14 | $0.0510 (17.02%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-11-27 | Meyers Rachel | Buy | 12 551 | Stock Option (Right to Buy) |
2023-11-27 | Meyers Rachel | Buy | 0 | |
2023-11-22 | Lucchino David L. | Sell | 110 | Common Stock |
2023-11-22 | Lucchino David L. | Sell | 230 | Common Stock |
2023-11-22 | Lucchino David L. | Sell | 614 | Common Stock |
INSIDER POWER |
---|
96.44 |
Last 81 transactions |
Buy: 3 077 272 | Sell: 64 406 |
音量 相关性
Frequency Therapeutics 相关性 - 货币/商品
Frequency Therapeutics 财务报表
Annual | 2022 |
营收: | $0 |
毛利润: | $0 (0.00 %) |
EPS: | $-2.33 |
FY | 2022 |
营收: | $0 |
毛利润: | $0 (0.00 %) |
EPS: | $-2.33 |
FY | 2021 |
营收: | $14 068.00 |
毛利润: | $14 068.00 (100.00 %) |
EPS: | $-0.00246 |
FY | 2020 |
营收: | $36.98M |
毛利润: | $36.98M (100.00 %) |
EPS: | $-0.820 |
Financial Reports:
No articles found.
Frequency Therapeutics
Frequency Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics to activate a person's innate regenerative potential to restore function. Its Progenitor Cell Activation approach uses small molecules and activate progenitor cells within the body to create functional tissue. The company's lead product candidate is FX-322, which is in Phase IIa clinical trial to treat the underlying cause of sensorineural hearing loss. It is also developing medicines for patients across a range of degenerative conditions, including multiple sclerosis, and diseases of the muscle, gastrointestinal tract, skin, and bone. The company has a license and collaboration agreement with Astellas Pharma Inc. for the development and commercialization of FX-322, as well as collaboration and licensing agreements with Massachusetts Eye and Ear, the Massachusetts Institute of Technology, The Scripps Research Institute, and Cambridge Enterprises Limited. Frequency Therapeutics, Inc. was incorporated in 2014 and is headquartered in Lexington, Massachusetts.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。